3-D QSAR Study Of Combretastatins Fused With Hetrocyclic Ring As Tubulin Binding Agents
Combretastatin A4 (CA4) is a leading agent in vascular disrupting strategies and tubulin polymerization inhibitor for the tumour therapy. A large number of combretastatin derivatives have been synthesized as potent inhibitors of Tubulin which are responsible for the anticancer activity. Combretastatins bind with the colchicine binding site of the tubulin and disrupt the dynamic equilibrium of tubulin. IN the current research proposal we have performed 3D-Field based QSAR on Combretastatins analogue in order to recognize structural features which are responsible for the tubulin inhibitors activity. The designed compounds are expected to show good inhibitory activity against tubulin when electrostatic group is attached in case of compounds 16 and 18, Bulky group is attached in case of compound 26 and hydrophobic group is attached in case of compound 51 respectively.